The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment.

作者: Kenshi Hayashida , Ichiro Nagasue , Takashi Fukuda , Atsuaki Gunji

DOI: 10.2188/JEA.12.22

关键词:

摘要: Interferon (IFN) therapy is used for the treatment of hepatitis C virus (HCV) disease, but so expensive that it creates controversy as to whether or not effective use limited health care resources. In order make this judgement possible, must be necessary build a comprehensive disease model HCV infection from social perspective. A Markov chain natural history in male patients was developed. Parameters on clinical phase were adopted published reports, those non-clinical estimated data blood donation and mortality rates disease. Then, adding modeling outcome IFN cost-benefit analysis, economically evaluated.Using model, shown (1) chronic (CHC) would beneficial at least Japanese situation, (2) complete response rate most sensitive factor affecting outcome, (3) younger person cured by therapy, greater benefit seen.These results demonstrate case CHC (male). J Epidemiol, 2002 ; 12: 22-32

参考文章(15)
John B Wong, Cost-effectiveness of treatments for chronic hepatitis C The American Journal of Medicine. ,vol. 107, pp. 74- 78 ,(1999) , 10.1016/S0002-9343(99)00388-5
Kenji Ikeda, Satoshi Saitoh, Isao Koida, Yasuji Arase, Akihito Tsubota, Kazuaki Chayama, Hiromitus Kumada, Masahiro Kawanishi, A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis Hepatology. ,vol. 18, pp. 47- 53 ,(1993) , 10.1002/HEP.1840180109
Yuji Kato, Keisuke Nakata, Shigenobu Nagataki, Katsuhisa Omagari, Ryuji Furukawa, Yukio Kusumoto, Iwao Mori, Heiichiro Tajima, Hajime Tanioka, Michitami Yano, Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer. ,vol. 74, pp. 2234- 2238 ,(1994) , 10.1002/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6
William G Bennett, Yuji Inoue, J Robert Beck, John B Wong, Stephen G Pauker, Gary L Davis, Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C Annals of Internal Medicine. ,vol. 127, pp. 855- 865 ,(1997) , 10.7326/0003-4819-127-10-199711150-00001
Raymond S. Koff, Interferon-alpha for chronic hepatitis C: reducing the uncertainties. Annals of Internal Medicine. ,vol. 127, pp. 918- 920 ,(1997) , 10.7326/0003-4819-127-10-199711150-00011
J. Garrott Allen, BLOOD-TRANSFUSION AND HEPATITIS The Lancet. ,vol. 306, pp. 1039- ,(1975) , 10.1016/S0140-6736(75)90323-2
Nobukazu Yuki, Norio Hayashi, Akinori Kasahara, Hideki Hagiwara, Tetsuo Takehara, Masahide Oshita, Kazuhiro Katayama, Hideyuki Fusamoto, Takenobu Kamada, Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C Journal of Hepatology. ,vol. 22, pp. 457- 463 ,(1995) , 10.1016/0168-8278(95)80109-X
Fumiko Sasaki, Junko Tanaka, Takashi Moriya, Keiko Katayama, Masataka Hiraoka, Kyuji Ohishi, Hideki Nagakami, Shunji Mishiro, Hiroshi Yoshizawa, Very Low Incidence Rates of Community-Acquired Hepatitis C Virus Infection in Company Employees, Long-Term Inpatients, and Blood Donors in Japan Journal of Epidemiology. ,vol. 6, pp. 198- 203 ,(1996) , 10.2188/JEA.6.198